We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+19.63%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$6.55B
AUM Growth
+$1.04B
Cap. Flow
+$118M
Cap. Flow %
1.81%
Top 10 Hldgs %
51.69%
Holding
171
New
48
Increased
43
Reduced
20
Closed
19

Top Buys

Rank Stock Value
1
CNC icon
Centene
CNC
+$177M
2
BMY icon
Bristol-Myers Squibb
BMY
+$109M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$96.7M
4
INSP icon
Inspire Medical Systems
INSP
+$91.9M
5
COGT icon
Cogent Biosciences
COGT
+$76M

Top Sells

Rank Stock Value
1
OSCR icon
Oscar Health
OSCR
+$250M
2
INDV icon
Indivior Pharmaceuticals
INDV
+$74.9M
3
BAX icon
Baxter International
BAX
+$47.7M
4
IDYA icon
IDEAYA Biosciences
IDYA
+$42.6M
5
UTHR icon
United Therapeutics
UTHR
+$38.6M

Sector Composition

Rank Sector Weight
1 Healthcare 91.55%
2 Real Estate 0.38%
3 Financials 0.07%
4 Consumer Staples 0.07%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIO icon
26
Bio-Rad Laboratories Class A
BIO
$8.15B
$63.4M 0.97%
226,070
– –
PHVS icon
27
Pharvaris
PHVS
$2.44B
$60.9M 0.93%
2,442,464
+425,000
+21% +$9.43M
IRON icon
28
Disc Medicine
IRON
$2.91B
$60.8M 0.93%
919,403
– –
IDYA icon
29
IDEAYA Biosciences
IDYA
$3.47B
$58.6M 0.89%
2,153,043
-1,762,268
-45% -$42.6M
BBOT
30
BridgeBio Oncology
BBOT
$686M
$56.6M 0.86%
+4,885,446
New +$50.9M
NVST icon
31
Envista
NVST
$4.35B
$46.7M 0.71%
2,294,036
+78,191
+4% +$1.61M
PRAX icon
32
Praxis Precision Medicines
PRAX
$8.77B
$44.6M 0.68%
840,851
+153,920
+22% +$7.46M
CRMD icon
33
CorMedix
CRMD
$661M
$38.7M 0.59%
+3,323,833
New +$40.2M
EHAB
34
DELISTED
Enhabit
EHAB
$38M 0.58%
4,747,746
-32,118
-0.7% -$242K
EMBC icon
35
Embecta
EMBC
$193M
$37M 0.56%
2,620,421
-129,291
-5% -$1.64M
CELC icon
36
Celcuity
CELC
$4.31B
$36.2M 0.55%
+733,530
New +$29.4M
CNMD icon
37
CONMED
CNMD
$1.3B
$35.8M 0.55%
760,196
+59,925
+9% +$3.11M
ZBIO
38
Zenas BioPharma
ZBIO
$1.86B
$34.7M 0.53%
1,562,942
– –
NEO icon
39
NeoGenomics
NEO
$1.9B
$34.3M 0.52%
4,447,331
+2,299,331
+107% +$16.1M
ARWR icon
40
Arrowhead Research
ARWR
$10.5B
$34.2M 0.52%
+993,000
New +$21.8M
DAWN
41
DELISTED
Day One Biopharmaceuticals
DAWN
$33.2M 0.51%
4,705,413
+982,282
+26% +$6.76M
KYMR icon
42
Kymera Therapeutics
KYMR
$9.52B
$32.4M 0.49%
572,258
-80,742
-12% -$3.64M
CDNA icon
43
CareDx
CDNA
$2.05B
$31.9M 0.49%
+2,191,000
New +$31.2M
ALNY icon
44
Alnylam Pharmaceuticals
ALNY
$35.7B
$31M 0.47%
67,935
-77,065
-53% -$31.4M
ACHC icon
45
Acadia Healthcare
ACHC
$3.17B
$29.4M 0.45%
+1,189,000
New +$26.5M
SION
46
Sionna Therapeutics
SION
$2.23B
$28.5M 0.44%
970,590
– –
SVRA icon
47
Savara
SVRA
$1.13B
$28.4M 0.43%
7,964,000
– –
PHR icon
48
Phreesia
PHR
$662M
$26.3M 0.4%
1,116,752
+102,175
+10% +$2.78M
MRNA icon
49
PUT
Moderna
MRNA
$24.5B
$25.8M 0.39%
+1,000,000
New +$27.9M
VCYT icon
50
Veracyte
VCYT
$4.72B
$24.9M 0.38%
726,000
+101,000
+16% +$2.9M
1
2
3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q3 2025 Portfolio in Review

As of Q3 2025, Deerfield Management held 171 positions worth $6.55B, up 19% from $5.51B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Deerfield Management's Q3 2025 filing shows 48 new, 43 increased, 20 reduced and 19 closed positions. Its largest new stake was Bristol-Myers Squibb: 2,337,771 shares worth $105M. The largest sale was Oscar Health, an estimated $250M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 89% a quarter earlier, followed by Real Estate and Financials.

  • Deerfield Management's largest Q3 2025 buy was Bristol-Myers Squibb: 2,337,771 shares worth $105M.
  • Deerfield Management added most to Centene in Q3 2025, an estimated $177M increase.
  • Deerfield Management's biggest Q3 2025 reduction was Indivior Pharmaceuticals, cutting an estimated $74.9M.
  • Deerfield Management fully exited Oscar Health in Q3 2025, selling an estimated $250M.
  • Deerfield Management's ten largest holdings make up 52% of its $6.55B portfolio in Q3 2025.
  • Deerfield Management opened 48 new positions and closed 19 in Q3 2025.
  • Deerfield Management's portfolio value rose 19% quarter-over-quarter to $6.55B.

Based on Deerfield Management's 13F filing for Q3 2025, filed 14 Nov 2025.